Related Experiment Video
Updated: May 29, 2026

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
Published on: August 25, 2022
Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for
Daniel B Herrick1, Wendy C Ziai, Carol B Thompson
1Department of Neurology, Johns Hopkins University, School of Medicine, BA, 1550 Orleans Street, CRB-II 3M50, Baltimore, MD 21231, USA. daniel.herrick@tufts.edu
Background And Purpose:
This is the first prospective evaluation of changes in systemic hematologic status following administration of intraventricular recombinant tissue-type plasminogen activator in patients with intraventricular hemorrhage (IVH).
Methods:
Laboratory data from subjects enrolled onto the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) Trials were analyzed. We analyzed pre- and post- recombinant tissue-type plasminogen activator dosing coagulation parameters. Longer-term changes in hematologic status were studied in subjects who received the study agent after blood clot in the third/fourth ventricles had resolved radiologically.
Results:
Plasma fibrinogen increased significantly in both treatment groups. Dosing did not have a significant impact on any systemic coagulation parameters in either treatment group.
Conclusions:
Intraventricular recombinant tissue-type plasminogen activator is unlikely to impact systemic coagulation or to compound the effects of systemic anticoagulation for deep venous thrombosis prophylaxis.
Clinical Trial Registration:
URL: http://clinicaltrials.gov. Unique identifier: NCT00650858.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Hemorrhagic Stroke ll: Pathophysiology

